U.S. develops 100% effective African swine fever vaccine, but commercialization is still a long way off

According to a report by the American Society for Microbiology, the U.S. government and academic experts have developed a vaccine against Swine Fever in Africa, which has been shown to be 100% effective in experiments. The vaccine was developed from a genetically modified strain of the African swine fever virus, which has been shown to be effective against the virus 28 days after vaccination, in low- and high-dose injections, the report said.

U.S. develops 100% effective African swine fever vaccine, but commercialization is still a long way off

“This new experimental african swine fever vaccine shows hope and provides complete protection for the strains currently erupting throughout Eastern Europe and Asia,” said Douglas Gladue, chief investigator of the USDA, which is involved in developing the vaccine. ”

Since the outbreak of swine fever in Africa, scientists from China to the United States have been racing to develop a vaccine against the virus, which is deadly to pigs but is known to be harmless to humans.

African swine fever was first discovered in Africa more than 100 years ago and there is no commercial vaccine for the disease. Despite 50 years of research, scientists have not been able to develop a vaccine that is safe and effective against Swine fever in Africa. In China, reports of unauthorized and tested vaccines surfaced last year, raising concerns that its use could exacerbate the problem.

The U.S. Department of Agriculture’s Gladue says the vaccine’s research began after an outbreak of the African swine fever virus in the Republic of Georgia in 2007. He says more needs to be done to meet regulatory requirements before commercialization.